Search Results
Results found for "David M. Thal"
- GASP1 enhances malignant phenotypes of breast cancer cells and decreases their response to...
was highly expressed in breast cancers, and patients harboring altered GASP1 showed a worse prognosis than
- Inside the New Dr. GPCR Ecosystem: Learning, Insight, and Momentum for 2026
Rather than chasing potency alone, this session equips drug hunters with system-level thinking: how
- Target Residence Time: The Hidden Driver of In Vivo Efficacy
Time” Now Only in Terry’s Corner Why Terry’s Corner In a world where drug discovery is evolving faster than
- How Fast Does a Drug Work?
Why Faster, Smarter Decisions Require More Than Kd In drug discovery today, the clock is always ticking
- Allosteric Binding Demystified: Smarter GPCR Drug Discovery
With Premium, you move faster, smarter, and more confidently than peers relying on scattered signals.
- Misread the Curve, Misjudge the Drug: Rethinking Antagonism in GPCR Pharmacology
Beyond the Curve: Questions This Lesson Helps You Answer This lesson pushes you to go deeper than surface-level
- GPCR Allosteric Modulation: Why Allostery is the Engine of Drug Discovery
Cryptic Sites, Longer Onset: Why Some Drugs Work Differently in Cells Than in Assays One of the most
- Why Intracellular Drugs May Hold the Key to GPCR Therapeutics
Intracellular Drugs” Now Only in Terry’s Corner Why Terry’s Corner In a world where GPCR science moves faster than
- Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic ...
It is predicted that more than 50 GPCRs are expressed in the liver.
- Platelets in the NETworks interweaving inflammation and thrombosis
In light of the current COVID-19 pandemic, the topic of immunothrombosis has become more relevant than
- Do You Believe AI Could Accelerate Drug Discovery?
Of 161 molecules tested, 42 substituted more than 50% of [³H]-LSD at 10 μM, achieving a 26% hit rate.
- Recurrent high-impact mutations at cognate structural positions in class A G protein-coupled ...
Because there are many more GPCRs than effectors, mutations in different receptors could perturb signaling
- Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST2 and SST5...
internalize both receptors whereas pasireotide promoted robust receptor internalization at shorter times than
- Is Your GPCR Drug Discovery Program Built for Breakthroughs or Breakdowns?
The GPCR Precision Blueprint is more than a concept.
- Predicting GPCR Function: Inside the Carlsson Lab’s Modeling Toolbox
method can’t resolve subtle potency differences, the team prefers to acknowledge that limitation rather than
- The Five Traps of Ignoring Kinetics
That’s your signal: kinetics are moving faster than your tools can measure.
- Curve Shifts Don’t Lie, But Your Eyes Might
against standards and across methods Trust that your conclusions reflect reality, not bias This is more than
- Understanding the Journey: Catherine Demery's Path to Addiction Science
She found herself drawn toward the science behind the drugs, rather than their clinical application.
- From Lab Logic to Leadership: How Scientific Thinking Holds Back Biotech Operations
direction, enabling others to move, and owning tradeoffs with imperfect inputs. 3️⃣ Do you explain more than
- A Note from Yamina: Building the Next Chapter of Dr. GPCR
Premium Members receive exclusive discounted access — making it easier than ever to deepen expertise
- TM5-TM6: structural switches that modulate the coupling of serotonin receptors to Gs or Gi
suggesting that the selectivity of the G-protein lies in intrinsic features of the receptor rather than
- Why Opposing Processes Matter for Your Next GPCR Drug
example, invites reflex bradycardia that blunts its heart rate liability—making it a better inotrope than
- Beyond Clearance: The Strategic Power of Irreversible Drug Binding
When a compound’s off-rate is slower than its clearance, its biological effect outlives its plasma presence
- From Snapshots to Predictions: Why Mechanism of Action Matters
mechanisms with confidence Apply models to design cost-efficient, informative experiments This is more than
- How Understanding Intracellular Drug Access Can Transform Your GPCR Drug Discovery Program
For drug discovery teams and scientists, staying ahead requires more than just reading papers—it demands
- FDA Approval Is a Strategy Obstacle, Not a Paperwork Problem
that sequence conceals a significant flaw; it treats FDA approval as the final checkpoint , rather than
- 📰 GPCR Weekly News, July 1 to 7, 2024
Submit your abstract today; you have less than two weeks!
- 📰 GPCR Weekly News, June 17 to 23, 2024
Epilepsy Models Biophysicists decipher functionality of adrenaline-binding receptor Tectonic plates more than
- Chemokine receptor-targeted drug discovery: progress and challenges
overexpressed and promote cancer progression, and use promiscuous non-peptide antagonists able to target more than
- Structural landscape of the Chemokine Receptor system
The chemokine system exhibits great versatility, with more than 50 chemokines interacting with over 20 Currently, there are more than 40 available structures of chemokines and their receptors in the Protein





















